A recent study from Koch Institute of Integrative Cancer Research, Department of Biology, MIT, Cambridge, USA shows that “p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular…. Liver Cancer.” This study was published in the July 31 2014 Cell (The number 1 journal in Basic biology) by Prof Scott W. Lowe, Darjus F. Tschaharganeh, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Insights into the treatment of Hepatocellular carcinomas and Cholangiocarcinomas: MiRNA-124 regulates the emergence of p53 mutant tumors via down regulation of its target gene. This study suggests that MiRNA-124, by decreasing the expression of Nestin, it may inhibit the emergence of p53 mutant hepatocellular carcinomas, Cholangiocarcinomas and other tumors. Together, this study suggests that pharmacological formulations encompassing“MiRNA-124 activators” may be used to treat Hepatocellular carcinomas and Cholangiocarcinomas.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Insights into the treatment of Hepatocellular carcinomas and Cholangiocarcinomas: MiRNA-107 regulates the emergence of p53 mutant tumors via down regulation of its target gene, 5/August/2014, 11.03 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation